EASL 2014: Abstract O8. SUCCESSFUL RETREATMENT WITH SOFOSBUVIR-CONTAINING REGIMENS FOR HCV GENOTYPE 2 OR 3 INFECTED PATIENTS WHO FAILED PRIOR SOFOSBUVIR PLUS RIBAVIRIN THERAPY
R. Esteban1, L. Nyberg2, J. Lalezari3, L. Ni4, B. Doehle4, B. Kanwar4, D. Brainard4, M. Subramanian4, W.T. Symonds4, J.G. McHutchison4, M. Rodriquez-Torres5, S. Zeuzem6
1Vall d’Hebron Hospital, Barcelona, Spain, 2Kaiser Permanente, San Diego, 3Quest Clinical Research and University of California-San Francisco, San Francisco, 4Gilead Sciences, Foster City, CA, 5Fundacion de Investigacion, San Juan, PR, United States, 6JW Goethe University Hospital, Frankfurt, Germany
Background and Aims: The efficacy of sofosbuvir (SOF)-containing regimens in patients who failed to achieve sustained virologic response (SVR) with SOF remains unknown. Given the lack of genotypic or phenotypic resistance to SOF in patients who did not achieve an SVR in the Phase 3 program, we designed an open-label study for relapsers to receive either a longer duration of SOF + RBV (24 weeks) or SOF + RBV with peginterferon (PEG-IFN).
Conclusions: Retreatment with sofosbuvir regimens of longer duration or with the addition of PEG-IFN in prior SOF failures results in high SVR4 rates and appears to offer a viable approach for GT-2 or GT-3 HCV infected patients who fail to achieve an SVR with SOF+RBV regimens.